Developing a vaccine using Vero cells for respiratory syncytial virus (RSV)
Official title: Task V08: Process Development for Scale-up of Vero Cells on Micro-Carriers for Manufacturing of a Live-Attenuated RSV Vaccine
Funded at Idt Biologika Gmbh · NIH-10329660 · Data updated 2026-11-12
This study is working on making a safe and effective vaccine to protect babies and young kids from respiratory syncytial virus (RSV), which often causes breathing problems, by improving how the vaccine is produced.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2021 |
| Award (this year) | $67,500 |
| NIH project number | 272201800011I-P00001-759301900311-1 |
| Project ID | NIH-10329660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include infants and young children who are at high risk for severe RSV infections.
✕Less likely to help
Patients who are not at risk for RSV infections or those who have already been vaccinated against RSV may not receive benefit from this research.
What this research studies
This research focuses on the development and manufacturing processes for a live-attenuated vaccine against respiratory syncytial virus (RSV) using Vero cells grown on micro-carriers. The project involves optimizing the production methods to ensure compliance with good manufacturing practices (cGMP) for clinical trials. Patients may benefit from this research as it aims to create a safe and effective vaccine to protect against RSV, a common cause of respiratory infections in infants and young children.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the incidence of RSV infections in vulnerable populations.
How similar studies have gone: Other research has shown success in developing vaccines using similar methodologies, indicating a promising approach for this project.
Where this research is happening
-
Idt Biologika Gmbh
Dessau-Rosslau, Germany Active
Researchers
- Principal investigator: Cristina, Arbelo — Idt Biologika Gmbh
- Study coordinator: Cristina, Arbelo
Related research
Other NIH-funded projects on the same topics.
-
Developing new vaccines for infectious diseases and bioterrorism
This study is all about creating new vaccines to help protect people from infectious diseases, including those that could come from bioterrorism or drug-resistant germs, so that patients can have better options for staying healthy.
-
Creating master cell banks for new SARS-CoV-2 vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, which could lead to more effective options for patients in the future.
-
Creating materials for testing new influenza vaccines
This study is working on creating and improving materials for new flu vaccines, which could help keep you and others safer from the flu and similar illnesses.
-
Creating master cell banks for new SARS-CoV-2 vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, so that patients can have more effective protection against the virus and its variants.
-
Creating vaccines and biologics to combat infectious diseases
This study is working on creating new vaccines to help protect people from infections like those caused by E. coli, so that patients can have better options for staying healthy and safe from serious diseases.
-
Developing a vaccine for Staphylococcus aureus
This study is working on creating a new vaccine to help protect people from Staphylococcus aureus infections, which can be tough to treat because the bacteria resist many antibiotics, and it aims to make this vaccine safe and effective for future use.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.